Speciality Medicines IPO Details: Price, Dates & Financials

Speciality Medicines reports PAT margin 16.49% and EBITDA margin 17.73%.

The debt-to-equity ratio of Speciality Medicines is 0.13. A lower ratio generally means the company relies less on borrowed money.

The price-to-book value (P/BV) of Speciality Medicines IPO is 2.19.

ROE (return on equity) shows profit earned on shareholders' money, ROCE (return on capital employed) shows profit earned on all capital used in the business, and RONW (return on net worth) measures return on the company's net worth. Higher figures usually indicate more efficient use of capital.

Compare ROE, ROCE, margins and P/BV of Speciality Medicines with listed companies in the same sector, and check the peer comparison given in the offer document. Ratios are only one input — they do not predict listing gains.

We require these key ratios to evaluate the financial health, profitability, valuation, and overall performance of the Speciality Medicines IPO. They help investors understand how efficiently the company operates, how much debt it carries, and whether its shares are reasonably valued compared with its earnings and assets for that specific Speciality Medicines IPO. These ratios also help assess the Speciality Medicines IPOs ability to generate profits, manage financial obligations, and deliver sustainable growth, enabling investors to make a more informed Speciality Medicines IPO investment decision.

Investors should examine the Speciality Medicines IPO's revenue growth, profitability, debt levels, cash flow, and earnings per share (EPS). These indicators help assess the Speciality Medicines IPO's financial stability, growth potential, and investment risks before investing in the Speciality Medicines IPO.